No translate

Nguyễn Thắng; Cao Thị Kim Hoàng; Nguyễn Hương Thảo

doi:10.58354/jvc.8485.2018.1143

Home

NGHIÊN CỨU LÂM SÀNG Issue: Số 84+85 , 2019 BỆNH MẠCH VÀNH

No translate

Published: October 19, 2026

10.58354/jvc.8485.2018.1143

Abstract

No translate

Keywords

No translate

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al (2017), “Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association”, Circulation 135(10):e146-e603.

DOI: doi.org/10.1161/cir.0000000000000491

2. Dugani S, Gaziano TA et al (2016), “25 by 25: Achieving Global Reduction in Cardiovascular Mortality”,

DOI: doi.org/10.1007/s11886-015-0679-4

Curr Cardiol Rep 18(1):10-015-0679-4.

3. World Health Organization (2017), “The top 10 causes of death”, Available at: http://www.who.int/ mediacentre/factsheets/fs310/en/#.V3Zz37Hy82I. Accessed April/14, 2017.

4. Nguyen VL, et al (2010), “Nghiên cứu mô hình bệnh tật ở bệnh nhân điều trị nội trú tại Viện tim mạch Việt Nam trong thời gian 2003-2007”, Journal of Vietnamese Cardiology 52:11-18 [Vietnamese].

5. Peterson ED, Roe MT, Mulgund J, at al (2006), “Association between hospital process performance and outcomes among patients with acute coronary syndromes”, J Am Med Assoc 295(16):1912-1920.

DOI: doi.org/10.1001/jama.295.16.1912

6. Shimony A, Grandi SM, Pilote L, et al (2014), “Utilization of evidence-based therapy for acute coronary syndrome in high-income and low/middle-income countries”, Am J Cardiol 113(5):793-797.

DOI: doi.org/10.1016/j.amjcard.2013.11.024

7. Yan AT, Yan RT, Tan M, et al (2007), “Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome”, Am Heart J 154(6):1108-1115.

DOI: doi.org/10.1016/j.ahj.2007.07.040

8. Redfern J, Hyun K, Chew DP, et al (2014), “Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand”, Heart 100(16):1281-1288.

DOI: doi.org/10.1136/heartjnl-2013-305296

10.

9. Berwanger O, Guimaraes HP, Laranjeira LN, et al (2012), “Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial”, JAMA 307(19):2041-2049.

DOI: doi.org/10.1001/jama.2012.413

11.

10. Sleight P (2000), “The HOPE Study (Heart Outcomes Prevention Evaluation)”, J Renin Angiotensin Aldosterone Syst 1(1):18-20.

DOI: doi.org/10.3317/jraas.2000.002

12.

11. Kassab YW, Hassan Y, Aziz NA, et al (2013), “Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice”, J Eval Clin Pract 19(4):658-663.

DOI: doi.org/10.1111/j.1365-2753.2012.01894.x

13.

12. Bainey KR, Armstrong PW, Fonarow GC, et al (2014), “Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program”, Circ Cardiovasc Qual Outcomes 7(2):227-235.

DOI: doi.org/10.1161/circoutcomes.113.000422

14.

13. Jernberg T, Hasvold P, Henriksson M, et al (2015), “Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective”, Eur Heart J 36(19):1163-1170.

DOI: doi.org/10.1093/eurheartj/ehu505

15.

14. Lee JH, Yang DH, Park HS, et al (2010), “Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value”, Am Heart J 159(6):1012-1019.

DOI: doi.org/10.1016/j.ahj.2010.03.009

16.

15. Tra J, van der Wulp I, Appelman Y, et al (2015), “Adherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome: a multicentre study”, Neth Heart J 23(4):214-221.

DOI: doi.org/10.1007/s12471-015-0664-y

17.

16. Al-Zakwani I, Zubaid M, Panduranga P, et al (2011), “Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: data from the gulf registry of acute coronary events”, Angiology 62(6):447-454.

DOI: doi.org/10.1177/0003319710394163

Tác giả

Nguyễn Thắng: Bộ môn Dược lý – Dược lâm sàng, Trường Đại học Y Dược Cần Thơ; Cao Thị Kim Hoàng: Bộ môn Dược lý – Dược lâm sàng, Trường Đại học Y Dược Cần Thơ; Nguyễn Hương Thảo: Bộ môn Dược lâm sàng, Đại học Y Dược Thành phố Hồ Chí Minh;